Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Rolls Out Zero-Tolerance Policy On ANDA Typos

Oct 03 2017

• By Derrick Gingery

FDA entrance sign 2016 — Fortunately for everyone, this sign is mistake free.

Related Content

GDUFA Success Depends On Industry Changes As Much As Review Improvements, FDA Says

Nov 04 2013

ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

Jul 27 2015

FDA To ANDA Sponsors: Don't Forget Quality When Rushing For 10-Month Review Goal

May 17 2016

ANDA Refuse-to-Receive Challenges Become More Common – And More Successful

Jul 20 2015

Manufacturers' Data Integrity Problems Remain FDA Investigators' Focus

May 18 2017

Additional Topics

United States Generic Drugs Review Pathway Regulation FDA BioPharmaceutical

More from Generics

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window